Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Momentum forward

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Nov 25, 2022 8:17pm

235 Views

Post# 35129448

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Momentum forward

From RBC report:
Valuation

Our $6.00 rounded price target is based on a blend of our DCF and 2030E P/E valuations. Our DCF at 20% yields a $5.21/sh valuation, and 15.0x 2027E Adj. EPS, discounted back at 20%, equates to $6.69/sh. Our discount rate and P/E multiple are relatively in line with valuations for development-stage oncology companies. We assume late-2024 FDA and EU approval of pelareorep in breast cancer and pancreatic cancer, peak US/EU penetration of ~4%, and a partnership agreement in 2023. Our price target supports our Outperform, Speculative Risk rating. Our Speculative Risk qualifier reflects the risk associated with a clinical-stage biotechnology company. Although ONC is running several different trials in various indications, there is no guarantee that the drug will reach the market.

Upside scenario

Our $18.00 upside scenario is based on positive results from the clinical programs. Important catalysts would be commencement of a Ph. III trial in breast cancer and potential clinical partnerships. Positive results from the other Phase II trials would significantly reduce the risk around developing the pelareorep program and have positive implications for moving forward with other indications. The potential for use of pelareorep in a range of therapeutic indications would materially change the trajectory of the stock.

<< Previous

Bullboard Posts

Next >>

Mining companies take action on reconciliation with First Nations